Synonym
Arfolitixorin monosulfate; Arfolitixorin sulfate; Arfolitixorin (sulfate);
IUPAC/Chemical Name
(2S)-2-[[4-[(6aR)-3-amino-1-oxo-2,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl]benzoyl]amino]pentanedioic acid;sulfuric acid
InChi Key
GKJSPWCDMPVQHB-KZCZEQIWSA-N
InChi Code
InChI=1S/C20H23N7O6.H2O4S/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29;1-5(2,3)4/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31);(H2,1,2,3,4)/t12-,13+;/m1./s1
SMILES Code
O=C(O)[C@@H](NC(C1=CC=C(N2CN3C4=C(N=C(N)NC4=O)NC[C@]3([H])C2)C=C1)=O)CCC(O)=O.O=S(O)(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
555.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Glimelius B, Stintzing S, Marshall J, Yoshino T, de Gramont A. Metastatic
colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy
backbone. Cancer Treat Rev. 2021 Jul;98:102218. doi: 10.1016/j.ctrv.2021.102218.
Epub 2021 May 4. PMID: 34015686.
2: Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N,
Pfeiffer P, Brændengen M, Mavroudis D, Taflin H, Skintemo L, Tell R,
Papadimitriou C. A phase I/II study of arfolitixorin and 5-fluorouracil in
combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in
metastatic colorectal cancer. ESMO Open. 2022 Oct;7(5):100589. doi:
10.1016/j.esmoop.2022.100589. Epub 2022 Sep 29. PMID: 36183444; PMCID:
PMC9588906.
3: Taflin H, Odin E, Carlsson G, Tell R, Gustavsson B, Wettergren Y. Plasma
deoxyuridine as a surrogate marker for toxicity and early clinical response in
patients with metastatic colorectal cancer after 5-FU-based therapy in
combination with arfolitixorin. Cancer Chemother Pharmacol. 2021
Jan;87(1):31-41. doi: 10.1007/s00280-020-04173-2. Epub 2020 Oct 24. PMID:
33099678; PMCID: PMC7801297.
